It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
(visit the link for the full news article)
TEN people with Parkinson's disease this week received injections of the first vaccine aimed at combating the condition.
Called PD01A, the drug primes the body's immune system to destroy alpha-synuclein, a protein thought to trigger the disease by accumulating in the brain and disrupting dopamine production.
Vienna, 5 June 2012. The world's first clinical study to develop Parkinson's vaccine is now being performed by the Vienna AFFiRiS. Dubbed the PD01A drug directed against a disease as responsible for reputable protein called alpha-synuclein and is currently being tested in a Phase I study of Parkinson's patients. The vaccine thus offers the prospect of treating the causes of Parkinson's disease and its potential for success prompted the U.S. Michael J. Fox Foundation to develop PD01A generous financial support. The Vienna-based study was designed to confirm the safety and tolerability of PD01A. To up to 32 patients are included in the study.
AFFiRiS AG announced today the launch of the Phase I study of its Parkinson's vaccine candidate PD01A known. The vaccine represents the world's first drug that targets a causal treatment of Parkinson's disease and is designed not only to symptomatic effects. PD01A will do the most specific for the (alpha-syn) and alpha-synuclein labeled protein involved in the development and progression of Parkinson's disease have a key role. By the vaccination is to stimulate the immune system to produce antibodies which are directed against alpha-syn. The study is performed in Vienna in the Confraternity private Josefstadt and include up to 32 patients.